8 results about "EP4 Receptor" patented technology

The present application relates to a compound represented by the general formula (I) (where all symbols represent the same meanings as those described in the specification) or a pharmaceutically acceptable salt thereof, which is useful as an EP4 agonist, and in particular, which has EP4 agonist activity, is selective to other PGE receptor subtypes, and has a low risk of toxicity to the circulatory system, and thus is useful as an active ingredient for preventing and / or treating diseases associated with the EP4 receptor.

Provided are a polymorph of an EP4 receptor antagonist, a preparation method therefor and a use thereof, relating in particular to a polymorph of an EP4 receptor antagonist(S)-4-(1-(2-(4-fluorobenzyl)-4, 7-dihydro-5H-thieno [2,3-c]pyran-3-carboxamido) ethyl) benzoic acid, a preparation method therefor and a use thereof. Compared with an amorphous form of a compound represented by formula I, the polymorph of the present invention has higher stability and better processing performance and is very suitable for being prepared into a medicine.

The present application provides a kind of compound shown in formula I, its tautomer, stereoisomer, hydrate, solvate, pharmaceutically acceptable salt or prodrug;The compound has effective antagonism to EP4, has good affinity with EP4 receptor, and can be used as EP4 antagonist.

The invention discloses a new application of 6-methoxysalicylic acid, namely application of 6-methoxysalicylic acid in preparation of a medicine for relieving convulsion and soothing nerves, through systematic pharmacological experiment research, it is found for the first time that 6-methoxysalicylic acid has EP4 receptor agonistic activity and can exert the effects of relieving convulsion and soothing nerves by specifically activating an EP4 receptor, and the 6-methoxysalicylic acid can be applied to preparation of medicines for relieving convulsion and soothing nerves. The symptoms such as palpitation and restlessness, sleep disorder and the like are effectively improved, and a new way is provided for treating diseases such as insomnia and the like.

The invention is directed to a series of novel heterobicyclic amide derivatives as EP4 receptor antagonists which are useful for treating diseases or conditions mediated by the action of PGE2 at EP4 receptors, such as pain, an inflammatory disease and cancer. Also within the scope of this invention are pharmaceutical compositions containing such compounds and methods of use of these compounds for treating a subject suffering from a condition mediated by the action of PGE2 at EP4 receptors.

The present invention relates to novel compounds of formula (I) and pharmaceutical compositions containing these compounds. The compounds provided herein can act as prostaglandin E2 (PGE2) EP4 receptor antagonists, which renders them highly advantageous for use in therapy, particularly in the treatment or prevention of cancer, a neovascular eye disease, inflammatory pain, or an inflammatory disease, such as, e.g., multiple sclerosis, rheumatoid arthritis or endometriosis.